Xilio Therapeutics, Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 02/13/2025 | 9.11 M | $8.70 M | 100.00% | 14.35% |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 02/14/2025 | 4.57 M | $4.36 M | 0.00% | 7.20% |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 02/14/2025 | 3.00 M | $2.87 M | 0.00% | 4.73% |
| MERCK & CO., INC. | 02/14/2025 | 1.48 M | $1.42 M | 100.00% | 2.34% |
| TAKEDA PHARMACEUTICAL CO LTD | 02/12/2025 | 1.48 M | $1.42 M | 0.00% | 2.32% |
| FMR LLC | 02/13/2025 | 1.40 M | $1.33 M | 0.00% | 2.20% |
| VANGUARD GROUP INC | 02/11/2025 | 902,531 | $861,918 | 0.00% | 1.42% |
| GEODE CAPITAL MANAGEMENT, LLC | 02/12/2025 | 358,422 | $342,334 | 5.98% | 0.56% |
| BALYASNY ASSET MANAGEMENT L.P. | 02/14/2025 | 343,230 | $327,785 | 25.96% | 0.54% |
| RENAISSANCE TECHNOLOGIES LLC | 02/13/2025 | 296,617 | $283,269 | 11.38% | 0.47% |
| TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 02/14/2025 | 249,635 | $238,401 | 100.00% | 0.39% |
| UBS GROUP AG | 02/14/2025 | 249,401 | $238,178 | 1,485.21% | 0.39% |
| FIL LTD | 02/13/2025 | 218,705 | $208,863 | 0.00% | 0.34% |
| BLACKROCK FUNDING, INC. /DE | 02/07/2025 | 76,086 | $72,662 | 0.61% | 0.12% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 02/14/2025 | 71,081 | $67,882 | 0.00% | 0.11% |
| RAYMOND JAMES FINANCIAL INC | 02/13/2025 | 50,086 | $47,832 | 100.00% | 0.08% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 02/14/2025 | 49,093 | $46,884 | 100.00% | 0.08% |
| STATE STREET CORP | 02/14/2025 | 43,390 | $41,437 | 0.00% | 0.07% |
| APTUS CAPITAL ADVISORS, LLC | 02/14/2025 | 41,000 | $39,155 | 100.00% | 0.06% |
| SEVENBRIDGE FINANCIAL GROUP, LLC | 02/12/2025 | 41,000 | $26,937 | 0.00% | 0.06% |
| MARINER, LLC | 02/13/2025 | 25,000 | $23,875 | -1.25% | 0.04% |
| STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 02/06/2025 | 20,000 | $19,100 | 0.00% | 0.03% |
| XTX TOPCO LTD | 02/13/2025 | 12,870 | $12,291 | -46.06% | 0.02% |
| TWO SIGMA INVESTMENTS, LP | 02/14/2025 | 10,824 | $10,337 | 4.19% | 0.02% |
| PINNACLE FINANCIAL GROUP, LLC / IL | 02/18/2025 | 10,000 | $9,550 | 0.00% | 0.02% |
| FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 02/14/2025 | 3,300 | $3,152 | 100.00% | 0.01% |
| TOWER RESEARCH CAPITAL LLC (TRC) | 02/13/2025 | 2,729 | $2,606 | -51.41% | 0.00% |
| KEY FINANCIAL INC | 01/31/2025 | 830 | $793 | 0.00% | 0.00% |
| PRIVATE WEALTH MANAGEMENT GROUP, LLC | 01/27/2025 | 310 | $297 | 0.00% | 0.00% |
| JPMORGAN CHASE & CO | 02/12/2025 | 66 | $63 | -12.00% | 0.00% |
| AVANTAX PLANNING PARTNERS, INC. | 02/07/2025 | 0 | $0 | -100.00% | 0.00% |
| MILLENNIUM MANAGEMENT LLC | 02/14/2025 | 0 | $0 | -100.00% | 0.00% |
| TWO SIGMA SECURITIES, LLC | 02/14/2025 | 0 | $0 | -100.00% | 0.00% |
| ENGINEERS GATE MANAGER LP | 02/14/2025 | 0 | $0 | -100.00% | 0.00% |
| DUNHILL FINANCIAL, LLC | 02/14/2025 | 0 | $0 | -100.00% | 0.00% |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Xilio Therapeutics, Inc. institutional Ownership - FAQ's
During the previous two years, 43 institutional investors and hedge funds held shares of Xilio Therapeutics, Inc.. The most heavily invested institutionals were:
GILEAD SCIENCES, INC.: 9.11 M
Bain Capital Life Sciences Investors, LLC: 4.57 M
Rock Springs Capital Management LP: 3 M
Merck & Co., Inc.: 1.48 M
TAKEDA PHARMACEUTICAL CO LTD: 1.48 M
FMR LLC: 1.4 M
39.69% of Xilio Therapeutics, Inc. stock is owned by institutional investors.
Institutional investors have bought a total of 27.88 M shares in the last 24 months. This purchase volume represents approximately $28.16 M in transactions.